This case study, developed by the Optimal CAB in Malawi with support from CHAI, outlines the efforts undertaken by Malawi CAB members to support the introduction of pediatric dolutegravir 10 mg (pDTG) in-country, focused in particular on raising awareness and creating demand.
Comments